.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
India introduced a major oncology breakthrough with the launch of subcutaneous lung cancer immunotherapy. Roche Pharma India recently received CDSCO approval for Tecentriq (atezolizumab) in this new format. Consequently, this innovation promises to transform treatment for metastatic non-small cell lung cancer (NSCLC) patients across the country.
Clinicians administer the new subcutaneous therapy in approximately seven minutes. In contrast, traditional intravenous infusions usually require several hours of hospital time. Therefore, medical teams can significantly optimize their resources. Specifically, hospital chairs can now accommodate up to five patients in the time previously needed for one. However, experts expect the market price to be slightly higher than the existing IV formulation.
Clinical data from global studies confirms that the formulation maintains comparable safety and efficacy to IV delivery. Moreover, healthcare professionals report that the new method simplifies the administration process. Importantly, four out of five patients preferred the subcutaneous route. Patients cited shorter clinic visits and reduced emotional stress as primary reasons for their choice. Additionally, this shift supports the growth of decentralized cancer care in daycare centers.
Q1: How does the new delivery method affect treatment time?
It reduces the administration time from several hours for IV infusion to approximately seven minutes for a subcutaneous injection.
Q2: Has the CDSCO approved this treatment for use in India?
Yes, the CDSCO approved the subcutaneous formulation for eligible adults with adjuvant and metastatic non-small cell lung cancer.
Q3: Is the efficacy of the subcutaneous version different from the IV version?
No, clinical trials such as IMscin001 have demonstrated comparable safety and efficacy profiles between the two formulations.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
India launches Roche's Tecentriq SC, a 7-minute subcutaneous lung cancer immunotherapy that reduces administration time by 80% and enhances patient comfort....
5 months ago
Annual health checks only offer static snapshots. Real-world evidence from 2.1 million insured Indians reveals that tracking dynamic biomarker trends over time enables clinicians to spot evolving cardiometabolic risks early, reverse borderline pathology, and deliver tailored preventive interventions.
Today
A nationwide cohort study published in JAMA Pediatrics reveals that maternal exposure to wildfire fine particulate matter, especially in late pregnancy, is linked to an elevated risk of childhood autism. Clinicians should evaluate ambient air quality risks and provide proactive protective counseling to mothers.
Today
India faces an escalating challenge with vascular diseases, where tobacco use and hypertension together drive substantial cerebrovascular mortality. Addressing nicotine addiction as a clinical neurochemical disorder rather than a lack of willpower is vital for nationwide prevention and sustainable cessation support.
Today
Modern 3D anthropometry reveals that pediatric leg growth ceases years before spinal elongation, exposing the clinical illusion of the classical Anderson-Green model. Learn how segmental growth dissociation improves surgical timing for epiphysiodesis in adolescent leg length discrepancy.
2 days back
With packaged goods giant HUL backing FSSAI's proposed front-of-pack red warning labels for foods high in fat, sugar, and salt, India takes a major step toward curbing non-communicable diseases. Learn how clearer nutrition disclosures empower clinicians, inform consumer choices, and drive dietary reform.
Today
